心力衰竭患者应用β-受体阻滞剂治疗的效果及生存质量的影响  

Effect of Treatment with β-blockers and Quality of Life in Patients with Heart Failure

作　　者：于春强[1] YU Chun-qiang(Department of Cardiology,Pizhou People's Hospital,Pizhou,Jiangsu Province,221300 China)

机构地区：[1]邳州市人民医院心内一科

出　　处：《中外医疗》2019年第29期41-43,共3页China & Foreign Medical Treatment

摘　　要：目的 分析心力衰竭患者行β-受体阻滞剂治疗的临床价值和对生存质量的改善效果。方法 以回顾性分析形式对该院于2016年12月-2017年12月期间收治的心力衰竭患者90例进行研究,采用抽签形式将90例患者均分为研究组和对照组,每组各为45例。对照组行利尿剂以及洋地黄等基础治疗。研究组配伍β-受体阻滞剂治疗,对比两组治疗后的心功能指标、14 d后两组患者生存质量评分以及治疗后药物不良反应发生率。结果 ①两组治疗前左心室射血分数、心输出血量、左心室舒张末期内径、左心室收缩末期内径队对比差异无统计学意义(t=0.137、0.490、0.036、0.046,P>0.05),治疗后研究组[(57.2±2.4)%、(4.90±0.62)L/min、(141.1±9.1)mm、(67.2±6.1)mm]优于对照组[(49.1±3.5)%、(4.65±0.53)L/min、(149.5±12.2)mm、(72.5±10.1)mm],两组对比差异有统计学意义(t=14.384、2.056、3.702、3.013,P<0.05);②治疗14 d后两组患者生存质量评分对比中可知,研究组躯体(52.12±4.73)分、角色(65.61±5.57)分、认知(51.90±5.91)分、情绪(54.74±7.87)分、社会(64.67±7.29)分和整体评分(52.25±6.78)分,均高于对照组[(48.24±5.10)分、(53.46±5.15)分、(42.04±5.15)分、(44.09±6.20)分、(52.21±6.31)分、(40.84±5.93)分],组间对比差异有统计学意义(t=3.742、10.744、8.438、7.131、8.669、8.498,P<0.05);③不良反应发生率分析中,研究组心动过缓2例、血压降低1例、肝功能异常1例,总发生率为4例(8.9%),对照组心动过缓3例、血压降低3例、肝功能异常2例,总发生率为8例(17.7%),组间对比差异无统计学意义(χ^2=1.538,P>0.05)。结论 将β-受体阻滞剂应用于心衰患者临床治疗中,其临床效果理想可行。Objective To analyze the clinical value of β-blockers in patients with heart failure and the improvement of quality of life.Methods A retrospective analysis of 90 patients with heart failure admitted to the hospital from December 2016 to December 2017 was conducted.All 90 patients were divided into study group and control group by lottery,45 cases each.The control group received basic treatments such as diuretics and digitalis.The study group was treated with β-blockers,and the cardiac function indexes after treatment,the quality of life scores of the two groups after 14 days,and the incidence of adverse drug reactions after treatment were compared.Results 1.The left ventricular ejection fraction,cardiac output,left ventricular end-diastolic diameter,and left ventricular end-systolic diameter were not statistically significant(t=0.137,0.490,0.036,0.046,P>0.05),after treatment,the study group[(57.2±2.4)%,(4.90±0.62)L/min,(141.1±9.1)mm,(67.2±6.1)mm]was superior to the control group[(49.1±3.5)%,(4.65±0.53)L/min,(149.5±12.2)mm,(72.5±10.1)mm],the two groups were statistically significant(t=14.384,2.056,3.702,3.013,P<0.05);2.after 14 days of treatment,the quality of life scores of the two groups were compared,the body of the study group(52.12±4.73)points,roles(65.61±5.57)points,cognition(51.90±5.91)points,emotions(54.74±7.87)points,social(64.67±7.29)points,and overall scores(52.25±6.78)points,all higher in the control group[(48.24±5.10)points,(53.46±5.15)points,(42.04±5.15)points,(44.09±6.20)points,(52.21±6.31)points,(40.84±5.93)points],the comparison between the groups was statistically significant(t=3.742,10.744,8.438,7.131,8.669,8.498,P<0.05);3.in the analysis of the incidence of adverse reactions,the study group bradycardia in 2 cases,1 case of blood pressure reduction and 1 case of abnormal liver function.The total incidence was 4 cases(8.9%),3 cases of bradycardia in control group,3 cases of blood pressure reduction,and 2 cases of liver function abnormality.The total incidence was 8 cases(17

关 键 词：Β-受体阻滞剂 心衰 生存质量 临床指标 不良反应 价值分析 

分 类 号：R4[医药卫生—临床医学]